Abstract:Streptococcus pyogenes is a human-specific pathogen that commonly colonizes the upper respiratory tract and skin, causing a wide variety of diseases ranging from pharyngitis to necrotizing fasciitis and toxic shock syndrome. S . pyogenes has a repertoire of secreted virulence factors that promote infection and evasion of the host immune system including the cytolysins streptolysin O (SLO) and streptolysin S (SLS). S . pyogenes does not naturally infect the upper respiratory tract of mice although mice transgenic for MHC class II human leukocyte antigens (HLA) become highly susceptible. Here we used HLA-transgenic mice to assess the role of both SLO and SLS during both nasopharyngeal and skin infection. Using S . pyogenes MGAS8232 as a model strain, we found that an SLS-deficient strain exhibited a 100-fold reduction in bacterial recovery from the nasopharynx and a 10-fold reduction in bacterial burden in the skin, whereas an SLO-deficient strain did not exhibit any infection defects in these models. Furthermore, depletion of neutrophils significantly restored the bacterial burden of the SLS-deficient bacteria in skin, but not in the nasopharynx. In mice nasally infected with the wildtype S . pyogenes , there was a marked change in localization of the tight junction protein ZO-1 at the site of infection, demonstrating damage to the nasal epithelia that was absent in mice infected with the SLS-deficient strain. Overall, we conclude that SLS is required for the establishment of nasopharyngeal infection and skin infection in HLA-transgenic mice by S . pyogenes MGAS8232 and provide evidence that SLS contributes to nasopharyngeal infection through the localized destruction of nasal epithelia. Streptococcus pyogenes is a human-specific bacteria that causes a massive global burden of disease, ranging from mild infections such as strep throat, to more serious diseases such as flesh-eating disease and toxic shock syndrome. S . pyogenes has two toxins, streptolysin O (SLO) and streptolysin S (SLS), which contribute to disease progression by causing cell death. The streptolysins have been extensively studied in mouse models of skin and invasive infections; however, their role in nasal infection is understudied. We found that removal of the SLS toxin from the bacteria caused a significant reduction in the infection burden of nasal and skin tissues in mice. Interestingly, the SLO toxin was not a major contributor to disease in either of these infection models. We provide evidence suggesting that SLS targets the mucosal barrier in the nasal tissues of mice to help cause nasal infection. We also show that SLS helps cause skin infection by protecting the bacteria from neutrophils. Overall, strep throat and skin infections are the main S . pyogenes diseases, and this work has the potential to guide the development of therapies to prevent and treat S . pyogenes infections by targeting SLS.

Multimodal Mass Spectrometry Identifies a Conserved Protective Epitope in S. pyogenes Streptolysin O

Development and characterization of a hemolysis inhibition assay to determine functionality of anti-Streptolysin O antibodies in human sera

An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome

A conserved three-dimensional pattern in a Streptococcus pyogenes M protein immunogen elicits M type cross-reactivity

Proteolytic Profiling of Streptococcal Pyrogenic Exotoxin B (SpeB) by Complementary HPLC-MS Approaches

Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization

Proteomics-based vaccine targets annotation and design of multi-epitope vaccine against antibiotic-resistant Streptococcus gallolyticus

Immunoinformatics design of novel multi-epitope vaccine against Trueperella Pyogenes using collagen adhesion protein, fimbriae, and pyolysin

Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus

Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes

The structure of pyogenecin immunity protein, a novel bacteriocin-like immunity protein from Streptococcus pyogenes

B-Cell Epitope Mapping of TprC and TprD Variants of Treponema pallidum Subspecies Informs Vaccine Development for Human Treponematoses

Novel Immunoprotective Proteins of Streptococcus Pneumoniae Identified by Opsonophagocytosis Killing Screen

An immunoinformatics approach for the design of a multi-epitope vaccine targeting super antigen TSST-1 of Staphylococcus aureus

Identification of a specific surface epitope of OmpC for Escherichia coli O157:H7 with protein topology facilitated affinity mass spectrometry

A flow cytometry-based assay to determine the ability of anti- Streptococcus pyogenes antibodies to mediate monocytic phagocytosis in human sera

Streptolysin S is required for Streptococcus pyogenes nasopharyngeal and skin infection in HLA-transgenic mice

Immunomodulating Enzymes from Streptococcus pyogenes—In Pathogenesis, as Biotechnological Tools, and as Biological Drugs

Immunoinformatic approach for multi-epitope vaccine design against Staphylococcus aureus based on hemolysin proteins

Integrated immunoinformatics and subtractive proteomics approach for multi-epitope vaccine designing to combat S. pneumoniae TIGR4

Simultaneous polyclonal antibody sequencing and epitope mapping by cryo electron microscopy and mass spectrometry - a perspective.